一次韭好的个人主页 - 老虎社区

一次韭好

暂无个人介绍

IP属地：广东

32关注

0粉丝

0主题

0勋章

05-16

Replying to @买股票的打铁匠:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//@买股票的打铁匠:你真是不懂，设计芯片和芯片代工厂是两码事。

04-26

代码都打错了

美银证券：重申信达生物(01810)“买入”评级上调目标价至61.1港元

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3494800443838167","uuid":"3494800443838167","gmtCreate":1531899978435,"gmtModify":1749060518296,"name":"一次韭好","pinyin":"ycjhyicijiuhao","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":32,"tweetSize":2,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.11","exceedPercentage":"80.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.24","exceedPercentage":"60.89%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.11","exceedPercentage":"80.44%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":9,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":435706009677976,"gmtCreate":1747409500534,"gmtModify":1747413379280,"author":{"id":"3494800443838167","authorId":"3494800443838167","name":"一次韭好","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494800443838167","authorIdStr":"3494800443838167"},"themes":[],"htmlText":"Replying to <a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//<a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:你真是不懂，设计芯片和芯片代工厂是两码事。","listText":"Replying to <a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//<a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:你真是不懂，设计芯片和芯片代工厂是两码事。","text":"Replying to @买股票的打铁匠:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//@买股票的打铁匠:你真是不懂，设计芯片和芯片代工厂是两码事。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/435706009677976","isVote":1,"tweetType":1,"viewCount":1079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":428359276040312,"gmtCreate":1745610509614,"gmtModify":1745619004521,"author":{"id":"3494800443838167","authorId":"3494800443838167","name":"一次韭好","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494800443838167","authorIdStr":"3494800443838167"},"themes":[],"htmlText":"代码都打错了","listText":"代码都打错了","text":"代码都打错了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/428359276040312","repostId":"2530597182","repostType":2,"repost":{"id":"2530597182","kind":"news","pubTimestamp":1745567816,"share":"https://www.laohu8.com/m/news/2530597182?lang=&edition=full","pubTime":"2025-04-25 15:56","market":"hk","language":"zh","title":"美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530597182","media":"金融界","summary":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","content":"<html><body><article><p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调<a href=\"https://laohu8.com/S/01801\">信达生物</a>(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。</p><p>信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键<span>资产</span>的长期销售预测。</p><p>本文源自：智通财经网</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 15:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01810":"小米集团-W","01801":"信达生物"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2530597182","content_text":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","news_type":1,"symbols_score_info":{"01801":1,"01810":1}},"isVote":1,"tweetType":1,"viewCount":718,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":435706009677976,"gmtCreate":1747409500534,"gmtModify":1747413379280,"author":{"id":"3494800443838167","authorId":"3494800443838167","name":"一次韭好","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494800443838167","authorIdStr":"3494800443838167"},"themes":[],"htmlText":"Replying to <a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//<a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:你真是不懂，设计芯片和芯片代工厂是两码事。","listText":"Replying to <a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//<a href=\"https://laohu8.com/U/10000000000010487\">@买股票的打铁匠</a>:你真是不懂，设计芯片和芯片代工厂是两码事。","text":"Replying to @买股票的打铁匠:哈哈哈哈哈就他懂，千亿老总的投资顾问都不如他//@买股票的打铁匠:你真是不懂，设计芯片和芯片代工厂是两码事。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/435706009677976","isVote":1,"tweetType":1,"viewCount":1079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":428359276040312,"gmtCreate":1745610509614,"gmtModify":1745619004521,"author":{"id":"3494800443838167","authorId":"3494800443838167","name":"一次韭好","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":9,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3494800443838167","authorIdStr":"3494800443838167"},"themes":[],"htmlText":"代码都打错了","listText":"代码都打错了","text":"代码都打错了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/428359276040312","repostId":"2530597182","repostType":2,"repost":{"id":"2530597182","kind":"news","pubTimestamp":1745567816,"share":"https://www.laohu8.com/m/news/2530597182?lang=&edition=full","pubTime":"2025-04-25 15:56","market":"hk","language":"zh","title":"美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530597182","media":"金融界","summary":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","content":"<html><body><article><p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调<a href=\"https://laohu8.com/S/01801\">信达生物</a>(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。</p><p>信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键<span>资产</span>的长期销售预测。</p><p>本文源自：智通财经网</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美银证券：重申信达生物(01810)“买入”评级 上调目标价至61.1港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-25 15:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01810":"小米集团-W","01801":"信达生物"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504251600129744b39c&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2530597182","content_text":"智通财经APP获悉，美银证券发布研报称，基于主要产品强劲销售，上调信达生物(01810)今明两年销售预测1%，把目标价从52港元上调至61.1港元，重申“买入”评级，基于强劲销售表现和稳健的产品线。信达生物今年2月旗下达伯舒及达攸同销售分别为1.79亿及1.14亿元人民币，同比升47.6%及32.3%，达伯华销售同比升15.4%至5,150万元人民币。同时，睿妥及Tafolecimab销售分别同比升53.2%及2.13倍。该行又指，公司宣布将在2025年ASCO年会上进行七场报告，其中三场关于达伯舒的新进展。因此上调部分关键资产的长期销售预测。本文源自：智通财经网","news_type":1,"symbols_score_info":{"01801":1,"01810":1}},"isVote":1,"tweetType":1,"viewCount":718,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}